---
layout: default
title: Ropinirole
description: "Ropinirole çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚åˆæ­¥è­‰æ“šç­‰ç´š L4ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 150
evidence_level: L4
indication_count: 10
---

# Ropinirole

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L4</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Ropiniroleï¼šå¾å¸•é‡‘æ£®æ°ç—‡åˆ°æ€è¦ºå¤±èª¿ç—‡

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Ropinirole å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Ropinirole åŸæœ¬ç”¨æ–¼æ²»ç™‚å¸•é‡‘æ£®æ°ç—‡åŠè…³éƒ¨èºå‹•ç—‡ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æ€è¦ºå¤±èª¿ç—‡ (schizophrenia)** æœ‰æ•ˆï¼Œé€™å€‹é æ¸¬ç²å¾—å¤šç¯‡ PubMed æ–‡ç»æ”¯æŒï¼ŒåŒ…å«ç³»çµ±æ€§å›é¡§åŠæ¡ˆä¾‹å ±å‘Šã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ²»ç™‚è‡ªç™¼æ€§å¸•é‡‘æ£®æ°ç—‡ã€åŸç™¼æ€§è…³éƒ¨èºå‹•ç—‡ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | attention deficit-hyperactivity disorderã€faciodigitogenital syndromeã€polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposisã€retinal dystrophy with or without extraocular anomaliesã€schizophreniaã€myopia X-linkedã€congenital disorder of glycosylation with defective fucosylationã€atypical glycine encephalopathyã€myopia 26, X-linked, female-limitedã€Charcot-Marie-Tooth disease, demyelinating, type 1G |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.90% |
| è­‰æ“šç­‰ç´š | L4 |
| å°ç£ä¸Šå¸‚ | éƒ¨åˆ†å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 11 å¼µï¼ˆéƒ¨åˆ†å·²è¨»éŠ·ï¼‰ |
| å»ºè­°æ±ºç­– | Worth Exploring |

## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. attention deficit-hyperactivity disorder</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Ropinirole æ˜¯ä¸€ç¨®å¤šå·´èƒº D2/D3 å—é«”ä¿ƒæ•ˆåŠ‘ï¼Œå…¶ä½œç”¨æ©Ÿè½‰èˆ‡æ€è¦ºå¤±èª¿ç—‡çš„å¤šå·´èƒºå‡èªªå¯†åˆ‡ç›¸é—œï¼š

1. **å¤šå·´èƒºå—é«”è¦ªå’ŒåŠ›**ï¼šRopinirole å° D2 å’Œ D3 å—é«”å…·æœ‰é«˜è¦ªå’ŒåŠ›ï¼Œé€™èˆ‡æ€è¦ºå¤±èª¿ç—‡çš„ç¥ç¶“ç”Ÿç‰©å­¸åŸºç¤ç›¸é—œã€‚

2. **è² æ€§ç—‡ç‹€æ”¹å–„æ½›åŠ›**ï¼šæ€è¦ºå¤±èª¿ç—‡çš„è² æ€§ç—‡ç‹€ï¼ˆå¦‚æƒ…æ„Ÿæ·¡æ¼ ã€ç¤¾äº¤é€€ç¸®ï¼‰èˆ‡çè³ç³»çµ±åŠŸèƒ½å—ææœ‰é—œï¼Œä¿ƒå¤šå·´èƒºè—¥ç‰©å¯èƒ½ä½œç‚ºè¼”åŠ©æ²»ç™‚ã€‚

3. **æŠ—ç²¾ç¥ç—…è—¥ç‰©å‰¯ä½œç”¨ç·©è§£**ï¼šæ–‡ç»é¡¯ç¤º Ropinirole å¯ç”¨æ–¼æ²»ç™‚ Aripiprazole å¼•èµ·çš„é²ç™¼æ€§éœåä¸èƒ½ã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡ Ropinirole ç”¨æ–¼æ€è¦ºå¤±èª¿ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

å…±æ‰¾åˆ° 15 ç¯‡ç›¸é—œæ–‡ç»ï¼š

### é—œéµæ–‡ç»

1. **Sabe et al. (2019)** - Journal of Clinical Psychopharmacology
   - æ¨™é¡Œï¼šProdopaminergic Drugs for Treating the Negative Symptoms of Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials
   - é¡å‹ï¼šç³»çµ±æ€§å›é¡§èˆ‡çµ±åˆåˆ†æ
   - é‡é»ï¼šä¿ƒå¤šå·´èƒºè—¥ç‰©å¯èƒ½ä½œç‚ºæ€è¦ºå¤±èª¿ç—‡è² æ€§ç—‡ç‹€çš„è¼”åŠ©æ²»ç™‚
   - [PubMed é€£çµ](https://pubmed.ncbi.nlm.nih.gov/31688399/)

2. **Michalopoulou et al. (2012)** - Journal of Clinical Psychopharmacology
   - æ¨™é¡Œï¼šRopinirole as an effective adjunctive treatment for clozapine-resistant negative symptoms in simple schizophrenia
   - é¡å‹ï¼šæ¡ˆä¾‹å ±å‘Š
   - é‡é»ï¼šRopinirole æˆåŠŸä½œç‚º Clozapine æŠ—è—¥æ€§è² æ€§ç—‡ç‹€çš„è¼”åŠ©æ²»ç™‚
   - [PubMed é€£çµ](https://pubmed.ncbi.nlm.nih.gov/22926612/)

3. **Maple et al. (2017)** - J Pharmacol Exp Ther
   - æ¨™é¡Œï¼šEffects of Repeated Ropinirole Treatment on Phencyclidine-Induced Hyperlocomotion, Prepulse Inhibition Deficits, and Social Avoidance in Rats
   - é¡å‹ï¼šå‹•ç‰©ç ”ç©¶
   - é‡é»ï¼šé‡è¤‡ Ropinirole æ²»ç™‚å¯æ”¹å–„æ€è¦ºå¤±èª¿ç—‡å‹•ç‰©æ¨¡å‹çš„ç—‡ç‹€
   - [PubMed é€£çµ](https://pubmed.ncbi.nlm.nih.gov/28167638/)

4. **Berger et al. (2011)** - Biological Psychiatry
   - æ¨™é¡Œï¼šcAMP response element binding protein phosphorylation in nucleus accumbens underlies sustained recovery of sensorimotor gating following repeated D2-like receptor agonist treatment in rats
   - é¡å‹ï¼šåŸºç¤ç ”ç©¶
   - é‡é»ï¼šæ­ç¤º D2 å—é«”ä¿ƒæ•ˆåŠ‘æ”¹å–„æ„Ÿè¦ºé‹å‹•é–˜æ§çš„åˆ†å­æ©Ÿåˆ¶
   - [PubMed é€£çµ](https://pubmed.ncbi.nlm.nih.gov/21035786/)

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. faciodigitogenital syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.92%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. retinal dystrophy with or without extraocular anomalies</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.91%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. schizophrenia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. myopia X-linked</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. congenital disorder of glycosylation with defective fucosylation</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. atypical glycine encephalopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.89%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. myopia 26, X-linked, female-limited</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.88%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. Charcot-Marie-Tooth disease, demyelinating, type 1G</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.88%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | ç‹€æ…‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|------|-----------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬025118è™Ÿ | åŠ›å¿…å¹³æŒçºŒæ€§è—¥æ•ˆè†œè¡£éŒ 2æ¯«å…‹ | æŒçºŒæ€§è—¥æ•ˆè†œè¡£éŒ  | æœ‰æ•ˆ | æ²»ç™‚å¸•é‡‘æ£®æ°ç—‡ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬025119è™Ÿ | åŠ›å¿…å¹³æŒçºŒæ€§è—¥æ•ˆè†œè¡£éŒ 4æ¯«å…‹ | æŒçºŒæ€§è—¥æ•ˆè†œè¡£éŒ  | æœ‰æ•ˆ | æ²»ç™‚å¸•é‡‘æ£®æ°ç—‡ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬025120è™Ÿ | åŠ›å¿…å¹³æŒçºŒæ€§è—¥æ•ˆè†œè¡£éŒ 8æ¯«å…‹ | æŒçºŒæ€§è—¥æ•ˆè†œè¡£éŒ  | æœ‰æ•ˆ | æ²»ç™‚å¸•é‡‘æ£®æ°ç—‡ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬022882è™Ÿ | åŠ›å¿…å¹³è†œè¡£éŒ 0.25æ¯«å…‹ | è†œè¡£éŒ  | æœ‰æ•ˆ | æ²»ç™‚è‡ªç™¼æ€§å¸•é‡‘æ£®æ°ç—‡ã€åŸç™¼æ€§è…³éƒ¨èºå‹•ç—‡ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬022883è™Ÿ | åŠ›å¿…å¹³è†œè¡£éŒ 1æ¯«å…‹ | è†œè¡£éŒ  | æœ‰æ•ˆ | æ²»ç™‚è‡ªç™¼æ€§å¸•é‡‘æ£®æ°ç—‡ã€åŸç™¼æ€§è…³éƒ¨èºå‹•ç—‡ |

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | ä¾†æº |
|-------------|---------|------|
| Morphine | ä¸­åº¦ | DDInter |
| Metoclopramide | ä¸­åº¦ | DDInter |
| Ethanol | ä¸­åº¦ | DDInter |
| Caffeine | ä¸­åº¦ | DDInter |
| Warfarin | ä¸­åº¦ | DDInter |
| Cimetidine | ä¸­åº¦ | DDInter |
| Promethazine | ä¸­åº¦ | DDInter |

### ç‰¹æ®Šæ³¨æ„äº‹é …

- **è¡å‹•æ§åˆ¶éšœç¤™é¢¨éšª**ï¼šæ–‡ç»å ±å‘Š Ropinirole å¯èƒ½å¢åŠ ç—…æ…‹æ€§è³­åšçš„é¢¨éšª
- **ç²¾ç¥ç—‡ç‹€**ï¼šå¯èƒ½å¼•ç™¼å­¤ç«‹æ€§å¦„æƒ³ç—‡å€™ç¾¤
- **å—œç¡**ï¼šå¯èƒ½å°è‡´çªç™¼æ€§ç¡çœ 

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šAlcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and...
- å»ºè­°ï¼šPatients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities r...


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**å¿ƒè¡€ç®¡ç–¾ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šThe pharmacokinetic disposition of ropinirole has not been studied in patients with hepatic impairment, however, the serum concentration of ropinirole...

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- é€šå¸¸ç„¡éœ€èª¿æ•´åŠ‘é‡ã€‚

**ä½è¡€å£“** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚

**Psychotic Disorders** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Neuroleptic Malignant Syndrome** ğŸŸ¢ Minor
- æ³¨æ„äº‹é …ï¼šNeuroleptic malignant syndrome (NMS) has not occurred during administration of ropinirole,  however, the syndrome has rarely been precipitated by rapi...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šWorth Exploring**

**ç†ç”±ï¼š**
1. å¤šå·´èƒºæ©Ÿè½‰èˆ‡æ€è¦ºå¤±èª¿ç—‡ç—…ç†ç”Ÿç†å­¸æœ‰æ˜ç¢ºé—œè¯
2. æœ‰æ¡ˆä¾‹å ±å‘Šæ”¯æŒå…¶ä½œç‚ºè² æ€§ç—‡ç‹€çš„è¼”åŠ©æ²»ç™‚
3. ç³»çµ±æ€§å›é¡§é¡¯ç¤ºä¿ƒå¤šå·´èƒºè—¥ç‰©é¡åˆ¥å¯èƒ½æœ‰æ•ˆ
4. å°ç£å·²æœ‰å¤šç¨®åŠ‘å‹ä¸Šå¸‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- éš¨æ©Ÿå°ç…§è©¦é©—è©•ä¼° Ropinirole è¼”åŠ©æ²»ç™‚æ€è¦ºå¤±èª¿ç—‡è² æ€§ç—‡ç‹€çš„ç™‚æ•ˆ
- æ›´è©³ç´°çš„å®‰å…¨æ€§è³‡æ–™ï¼Œç‰¹åˆ¥æ˜¯èˆ‡æŠ—ç²¾ç¥ç—…è—¥ç‰©ä½µç”¨æ™‚
- å»ºç«‹é©ç•¶çš„èµ·å§‹åŠ‘é‡å’Œæ»´å®šæ–¹æ¡ˆ

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Riluzole]({{ "/drugs/riluzole/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Aluminum Oxide]({{ "/drugs/aluminum_oxide/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Tetryzoline]({{ "/drugs/tetryzoline/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Minoxidil]({{ "/drugs/minoxidil/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Pralatrexate]({{ "/drugs/pralatrexate/" | relative_url }}) - è­‰æ“šç­‰ç´š L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Ropiniroleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/ropinirole/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_ropinirole,
  title = {Ropiniroleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/ropinirole/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
